BI Asset Management Fondsmaeglerselskab’s Edwards Lifesciences EW Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.1M	Buy	34,266 +3,155	+10%	+$264K	0.02%	348
2026 Q1	$2.49M	Sell	31,111 -18,895	-38%	-$1.56M	0.03%	347
2025 Q4	$4.26M	Buy	50,006 +4,876	+11%	+$400K	0.04%	291
2025 Q3	$3.51M	Buy	45,130 +19,506	+76%	+$1.52M	0.03%	316
2025 Q2	$2M	Sell	25,624 -30,563	-54%	-$2.28M	0.02%	360
2025 Q1	$4.07M	Sell	56,187 -16,432	-23%	-$1.18M	0.05%	255
2024 Q4	$5.38M	Buy	+72,619	New	+$5.08M	0.06%	224
2024 Q3	–	Sell	-73,604	Closed	-$6.8M	–	634
2024 Q2	$6.8M	Buy	73,604 +40,531	+123%	+$3.59M	0.11%	164
2024 Q1	$3.16M	Sell	33,073 -162,969	-83%	-$13.7M	0.06%	218
2023 Q4	$14.9M	Buy	196,042 +28,792	+17%	+$2M	0.32%	83
2023 Q3	$11.6M	Sell	167,250 -9,205	-5%	-$740K	0.27%	93
2023 Q2	$16.6M	Sell	176,455 -19,560	-10%	-$1.7M	0.39%	69
2023 Q1	$16.2M	Sell	196,015 -8,873	-4%	-$697K	0.43%	63
2022 Q4	$15.3M	Buy	204,888 +23,423	+13%	+$1.81M	0.41%	71
2022 Q3	$15M	Sell	181,465 -2,615	-1%	-$252K	0.76%	36
2022 Q2	$17.5M	Buy	184,080 +7,284	+4%	+$754K	0.75%	44
2022 Q1	$20.8M	Sell	176,796 -15,051	-8%	-$1.69M	0.8%	42
2021 Q4	$24.9M	Sell	191,847 -11,929	-6%	-$1.39M	0.92%	29
2021 Q3	$23.1M	Sell	203,776 -1,828	-0.9%	-$209K	0.87%	29
2021 Q2	$21.3M	Buy	205,604 +9,291	+5%	+$876K	0.82%	35
2021 Q1	$16.4M	Buy	196,313 +123,660	+170%	+$10.5M	0.67%	49
2020 Q4	$6.63M	Buy	72,653 +10,646	+17%	+$883K	0.29%	81
2020 Q3	$4.95M	Buy	62,007 +13,394	+28%	+$1.05M	0.22%	97
2020 Q2	$3.36M	Sell	48,613 -1,820	-4%	-$129K	0.17%	121
2020 Q1	$3.17M	Buy	50,433 +17,211	+52%	+$1.24M	0.19%	98
2019 Q4	$2.58M	Buy	33,222 +27,519	+483%	+$2.15M	0.12%	158
2019 Q3	$418K	Sell	5,703 -708	-11%	-$49.7K	0.02%	292
2019 Q2	$395K	Buy	+6,411	New	+$388K	0.02%	171

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's EW Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab increased its Edwards Lifesciences (EW) stake by 10% in Q2 2026, buying an estimated $264K and bringing the position to 34,266 shares worth $3.1M. The position accounts for 0.02% of the portfolio, ranked #348.

BI Asset Management Fondsmaeglerselskab first reported a position in EW in Q2 2019 and has held it in 28 quarters since. The position peaked at $24.9M in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

BI Asset Management Fondsmaeglerselskab held 34,266 shares of Edwards Lifesciences worth $3.1M as of Q2 2026.
BI Asset Management Fondsmaeglerselskab bought 3,155 Edwards Lifesciences shares in Q2 2026, an estimated $264K.
Edwards Lifesciences made up 0.02% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #348 holding.
BI Asset Management Fondsmaeglerselskab first reported a position in Edwards Lifesciences in Q2 2019 and has held it in 28 quarters since.
BI Asset Management Fondsmaeglerselskab's Edwards Lifesciences position peaked at $24.9M in Q4 2021.
1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.